Author: Frank Salopek

This may seem like a simple question, but when you consider the factors that impact data quality, it is quite complex.   Not unlike other businesses, pharma relies on a rich flow of data for making and assessing strategic decisions. For pharma, data comes from many different sources. The ability to capture patient data from multiple disparate sources, such as SP and HUB data, and integrate it...

Read More

The future of medicine is being driven by technology as a part of scientific discovery. Precision medicine, an emerging treatment paradigm, aims to find the right therapy at the right time based on an individual's unique genetic background,. Studies of phenotypes and genotypes, along with the use of Artificial Intelligence (AI), have provided vast and expanding knowledge of how genomics play a role in determining...

Read More

A recent news headline by Reuters: “Modern vaccine trial contractors fail to enroll enough minorities, prompting slowdown”   The COVID-19 pandemic has shed new light on a decades-old problem related to recruitment in clinical trials: under-enrollment among racial and ethnic minorities.  In order to truly understand the efficacy and safety of new medicines, including COVID-19 vaccines and therapies, as well as generalize research findings, a cross-section of...

Read More

Imagine that your company is preparing to launch a new branded drug with distinct advantages in efficacy and side-effect profile. You are challenged by a crowded market dominated by generics.  Ninety-six percent of the market share is shared across multiple generics; three other branded products compete for the remaining 4%. The market value is high, so dominating the branded competitors is not only a significant...

Read More
MSA value added benefits

When selecting a partner for the de-identification, integration, and management of patient data — while securing patient privacy — it's important to ensure the use of the right technologies and processes. It's equally as important to weigh the value of all the additional benefits (service, flexibility, etc.) a potential partner provides.   Providing best-in-class de-identification and matching capabilities, MSA offers the most credentialed, most configurable, and most trusted data management solutions,...

Read More
Healthcare Data Management

Over the past decade, the distribution model for medication delivery has evolved from retail pharmacies and mail order to Specialty Pharmacies (SP), 340B Contract Pharmacies, and Rare Disease Pharmacies. In addition, large health systems are continuing the trend of market consolidation by purchasing physician practices, smaller regional hospitals, long-term care facilities and other ancillary healthcare services. These health systems are using their size and influence...

Read More

Pharma is facing the many challenges of COVID-19 head-on. Leading organizations are taking full advantage of today’s sophisticated analytic tools, including state-of-the-art anonymization technologies that seamlessly link patient data across multiple sources, to monitor the impact of COVID-19 on treatments in new ways.   Since the COVID-19 pandemic began, the industry has been primarily focused on understanding the journey of severely ill, older adults requiring hospitalization. More...

Read More

Did you know that 70% of medical diagnosis are informed by clinical lab results data?   Over the past five months, round-the-clock news reports have kept us well informed of data related to patients testing positive for COVID-19. People everywhere have been closely following this data in an attempt to gauge – and hopefully control – the impact of the virus.   Critical insights about the patient journey can,...

Read More

MSA’s Healthcare Data Management experts provide solutions that empower pharma to better understand the impact of COVID-19 on the diabetes patient journey by linking clinical lab results, prescriptions, EMR, and medical claims data – all while protecting patient privacy. MSA, provider of the industry’s most credentialed, configurable, and trusted de-identification and data management solutions, accurately anonymizes and seamlessly links disparate data from one or multiple...

Read More

A close examination of the COVID-19 patient journey will result in a better understanding of the impact of the virus on at-risk diabetes patients. Segmenting positive and negative COVID-19 patients provides a real world comparison of anonymized patient cohorts’ A1C, fasting blood sugars, and glucose levels. Linked with prescribed medications, this data will identify the impact of COVID-19 on the patients’ prescribed drug therapy. The...

Read More